Sign in

EIKN on Nasdaq

Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. is an American biological products company based in Hayward, incorporated in Delaware.1 Its shares trade on Nasdaq under the symbol EIKN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerEIKN on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersMillbrae, California1
  • Incorporated inDE2
  • Business address230 Harriet Tubman Way, Millbrae, Ca 940302
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Eikon Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Eikon Therapeutics, Inc.

  • Eikon Therapeutics, Inc. Millbrae, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Eikon Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

We currently lease approximately 285,000 square feet of space at our corporate headquarters in Millbrae, California. The Millbrae lease expires in January 2040. We also currently lease and sublease a total of approximately 125,000 square feet of space across two different properties in Hayward, California, for use as office and research and development space. These leases and subleases expire between October 2026 and July 2029. We currently lease approximately 13,000 square feet of space in New York, New York, which expires in June 2028, for use as research and development space, and approximately 36,000 square feet of space in Jersey City, New Jersey, which expires in July 2027, to serve as our East Coast headquarters. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led Eikon Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Alfred Lloyd Bowie Jr.2026–now

Chief operating officer

  1. Michael A. Klobuchar2026–now
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerAshish M. Kheterpal named Jun 1, 202314
  • Executive OfficerBarbara M. Howes named Jun 1, 202314
  • Executive OfficerDan M. Anderson named Jun 1, 202314
  • Executive OfficerRoy M. Banes named Jun 1, 202314
  • Executive OfficerRuss M. Berman named Jun 1, 202314
  • DirectorDror M. Berman named Jan 6, 2022 to Feb 28, 202515
  • DirectorJames M. Tananbaum named Jan 6, 2022 to Feb 28, 202515
  • DirectorJoshua M. Wolfe named Feb 28, 202515
  • DirectorRobbie M. Huffines named Feb 28, 202515
  • DirectorRobin M. Washington named Jun 1, 2023 to Feb 28, 202515
  • DirectorJosh M. Wolfe named Jun 1, 202314
  • DirectorAdam M. Goulburn named Jan 6, 202216

Timeline

  1. Aug 14, 20268-K Regulation FD disclosure17
  2. Aug 13, 20268-K Results of operations18
  3. Aug 3, 20268-K Executive or director change19
  4. Jun 10, 20268-K Executive or director change20
  5. Jun 1, 20268-K Regulation FD disclosure; Other events21
  6. May 11, 20268-K Results of operations; Regulation FD disclosure22
  7. Mar 30, 20268-K Results of operations23
  8. Feb 6, 20268-K Bylaws or fiscal year changed24

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202625

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results18
  2. May 11, 2026Reported quarterly or annual results22
  3. Mar 30, 2026Reported quarterly or annual results23

Drug trials and FDA: coming up

  1. Dec 2026Phase 2 trial readout expected Phase 2 trial of EIK1001, Pembrolizumab and others in NSCLC: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06246110).26
  2. Jun 1, 2027Phase 1/2 trial readout expected Phase 1/2 trial of IMP1734 in Advanced Solid Tumor: primary completion expected Jun 1, 2027 (ClinicalTrials.gov NCT06253130).27

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

64 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 8 major events, 28 insider forms, 10 large holders, 3 private raises, 12 other. The latest 20:

  1. Oct 7, 2026SCHEDULE 13G/A EDGAR
  2. Oct 2, 2026SCHEDULE 13G/A EDGAR
  3. Sep 8, 20264 EDGAR
  4. Aug 14, 20268-K EDGAR
  5. Aug 13, 202610-Q EDGAR
  6. Aug 13, 20268-K EDGAR
  7. Aug 6, 2026SCHEDULE 13G/A EDGAR
  8. Aug 3, 20268-K EDGAR
  9. Jun 15, 20263 EDGAR
  10. Jun 10, 20268-K EDGAR
  11. Jun 1, 20268-K EDGAR
  12. May 15, 2026SCHEDULE 13G EDGAR
  13. May 13, 2026SCHEDULE 13G EDGAR
  14. May 11, 202610-Q EDGAR
  15. May 11, 20268-K EDGAR
  16. May 6, 2026SCHEDULE 13G EDGAR
  17. Apr 29, 2026SCHEDULE 13G EDGAR
  18. Mar 30, 20268-K EDGAR
  19. Mar 30, 202610-K EDGAR
  20. Mar 4, 20264 EDGAR

The 64 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 3, 2026Kutzkey Tim10% ownerBuy89,200$11.56$1.0MForm 4
Feb 6, 2026Column Group Opportunity III, LP10% ownerBuy2,117,760$18.00$38.1MForm 4
Feb 4, 2026FRAZIER KENNETH CDirectorBuy111,111$18.00$2.0MForm 4
Feb 4, 2026Wolfe JoshDirectorBuy277,776$18.00$5.0MForm 4
Feb 4, 2026Lux Ventures V, L.P.10% ownerBuy277,776$18.00$5.0MForm 4
Feb 4, 2026Foresite Capital Opportunity Management V, LLC10% ownerBuy55,555$18.00$1.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.0B 2021–2025
Money received by yearMoney received by year, 2021–2025: $1.0B in all. Private raises (Form D) $1.0B.$0$200M$400M$600M2021 · Private raises (Form D): $517.8M202120222023 · Private raises (Form D): $140.8M202320242025 · Private raises (Form D): $350.7M2025
Figures by year
YearPrivate raises (Form D)Total
2025$350.7M$350.7M
2023$140.8M$140.8M
2021$517.8M$517.8M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Feb 14, 2025Raised $350.7 million in a private offering of equity15 Form D: $400 million offered in all Form D
  2. May 18, 2023Raised $140.8 million in a private offering of equity14 Form D: $535 million offered in all Form D
  3. Dec 3, 2021Raised $517.8 million in a private offering of equity16 Form D: $525 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 77. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC4,993,906$65.2M0.0%+1,157,076
BlackRock, Inc.4,281,425$55.9M0.0%+962,046
Foresite Capital Management IV, LLC1,943,682$25.4M8.7%No change
Merck & Co., Inc.1,666,666$21.7M4.1%No change
Foresite Capital Management V, LLC1,318,983$17.2M4.8%No change
Capital World Investors1,175,944$15.3M0.0%+32,307
Vanguard Capital Management LLC922,707$12.0M0.0%−46,724
EcoR1 Capital, LLC732,606$9.6M0.5%No change
Geode Capital Management, LLC556,955$7.3M0.0%+283,024
Baker Bros. Advisors LP555,555$7.2M0.0%No change
Alliancebernstein L.P.641,888$6.8M0.0%−380,300
Soros Capital Management LLC484,672$6.3M1.1%No change
StepStone Group LP395,340$5.2M0.2%No change
Canada Pension Plan Investment Board379,024$4.9M0.0%No change
State Street Corp354,093$4.6M0.0%+313,943
Franklin Resources Inc350,000$4.6M0.0%No change
General Catalyst Group Management, LLC305,233$4.0M2.1%No change
UBS Group AG263,932$3.4M0.0%+164,524
Parkman Healthcare Partners LLC256,053$3.3M0.3%New
Charles Schwab Investment Management Inc182,105$2.4M0.0%+51,026
Schonfeld Strategic Advisors LLC179,775$2.3M0.0%New
Northern Trust Corp175,927$2.3M0.0%+130,396
Ensign Peak Advisors, Inc170,490$2.2M0.0%−29,510
Vanguard Portfolio Management LLC148,895$1.9M0.0%+135,282
Vanguard Fiduciary Trust Co148,410$1.9M0.0%+16,456

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Eikon Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREikon Therapeutics, Inc.1
  • CIK0001861123
  • Employer ID (EIN)84-28075861
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address230 Harriet Tubman Way, Millbrae, CA 940301
  • Phone341-777-05661
  • Shares outstanding54,165,030 as of Aug 3, 202635
  • On EDGAR sinceMay 13, 20211
  • Filings65 in all: 3 (14), 4 (14), 8-K (8), SCHEDULE 13G (6), D (4), DRS/A (3), SCHEDULE 13G/A (3), 10-Q (2)1
    All 19 form types

    10-K (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Latest 8-K (8-K) Aug 14, 2026

Risk factors and legal proceedings

The risks Eikon Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 73 risks under these headings, as written.3

  • Risks Related to Our Business, Limited Operating History, and Financial Position
  • We are a late clinical-stage biotechnology company with a limited operating history and a history of incurring substantial net losses, have no products approved for commercial sale, have never generated revenue from product sales, and may never achieve or maintain profitability.
  • We will require substantial additional capital to finance our operations and achieve our business objectives. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and product development programs or future commercialization efforts.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or current or future product candidates.
  • Our business depends entirely on the success of our product candidates and development programs, including EIK1001, EIK1003, EIK1004, EIK1005, EIK1006, and our ARv7 program, and we cannot guarantee that any or all of our current or future product candidates will successfully complete clinical development, receive regulatory approval, or be successfully commercialized. If we are unable to develop, receive regulatory approval for, and successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
  • We may not be successful in applying our technology platform to identify or develop safe, effective, or commercially viable product candidates.
  • We are dependent on the services of our key leaders, and our future success depends on our ability to retain these individuals and to attract and retain qualified personnel.
  • We use AI/ML to enable our analysis of the internal data generated from our technology platform, and for certain other uses in connection with our business. Defects in, or loss of access to, our data may impair our ability to discover or develop targets or product candidates.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any product candidates, which could adversely affect our business, financial condition, results of operations, and prospects.
  • Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could adversely affect our business, financial condition, results of operations, and prospects.
  • We have entered, and may in the future enter, into additional collaboration arrangements, which are important to our business. If we are unable to enter into new collaborations, or if we fail to realize the benefits of any current or future collaboration arrangements, our business, financial condition, results of operations, and prospects could be adversely affected.
  • We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, which could result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.
The other 62 risks
  • We may become subject to litigation, which could result in substantial costs and divert management’s attention and resources from our business.
  • We or the third parties upon whom we depend may be adversely affected by natural or manmade disasters.
  • Unfavorable global economic conditions, including any adverse macroeconomic conditions or geopolitical events, could adversely affect our business, financial condition, results of operations, or prospects.
  • Changes in U.S. government policies, including those with respect to China, increased tariffs, and reductions in federal research funding, could adversely affect our business.
  • Risks Related to Research, Development, and Commercialization
  • Many of our product candidates/programs are still in preclinical or early-stage clinical development. We have not yet completed any pivotal clinical trials with our product candidates, and we may be unable to do so for any product candidates we are currently developing or may develop in the future. If we are unable to advance our product candidates through clinical development, obtain regulatory approval, and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
  • Preclinical and clinical development is a lengthy and expensive process, with uncertain timelines and uncertain outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product candidates or any of our future product candidates on a timely basis, or at all.
  • The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, or if regulatory approval we do obtain is limited, our business will be substantially harmed.
  • If we encounter delays or difficulties enrolling or retaining patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected, which could adversely affect our business, financial condition, results of operations, and prospects.
  • Positive results from preclinical studies and early clinical trials of our current or future product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our current or future product candidates. If we cannot replicate the positive results from preclinical studies and early-stage clinical trials of our current or future product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for, and commercialize our current or future product candidates.
  • Interim, top-line, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may experience delays in commencing and completing, or ultimately be unable to complete, the development and/or commercialization of our product candidates.
  • We may expend our limited resources to pursue a particular product candidate in specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements, or experience unanticipated problems with our product candidates.
  • Even if our product candidates are approved, if they do not achieve broad market acceptance, the revenue that we generate from their sales will be limited.
  • The market opportunities for our product candidates and forecasts of market growth are subject to numerous uncertainties and may not be accurate, and the actual market for our product candidates may be smaller than we estimate. Even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.
  • We face substantial competition, which may result in others discovering, developing, or commercializing similar drugs before or more successfully than we do.
  • If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our programs may be delayed and our expenses may increase.
  • Use of our product candidates could be associated with side effects, adverse events, or safety risks, which could cause us to suspend or discontinue clinical trials, cause us to abandon a product candidate, delay or preclude approval, prevent market acceptance, require us to conduct product recalls, limit the commercial profile of an approved label, cause regulatory authorities to withdraw product approvals, or result in other significant negative consequences that could severely harm our business, results of operations, financial condition, and prospects.
  • Changes in product candidate manufacturing, formulation, or analytical methods may result in additional costs or delay, which could adversely affect our business, financial condition, results of operations, and prospects.
  • A variety of risks associated with collaborating with third parties overseas, including in China, conducting research and clinical trials abroad, and seeking to market our product candidates internationally, could materially adversely affect our business, financial condition, results of operations, and prospects.
  • We are conducting and intend to conduct certain of our clinical trials globally. However, the FDA and comparable foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.
  • The manufacturing process for any products that we may develop is subject to the FDA or comparable foreign regulatory authority approval process, and we must therefore contract with manufacturers who can meet our and all applicable FDA or comparable foreign regulatory authority requirements on an ongoing basis.
  • We intend to pursue the development of certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.
  • Risks Related to Intellectual Property
  • If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and any future product candidates we may develop, or enforce such intellectual property rights, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely affected.
  • We cannot ensure that patent rights relating to inventions described and claimed in our or our licensors’ pending patent applications will issue, or that patents that issue in the future will not be challenged and rendered invalid or unenforceable.
  • Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive products.
  • We may not be successful in obtaining or maintaining necessary rights to develop current and any future product candidates on acceptable terms.
  • Any product candidates licensed from third parties may be subject to retained rights.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates. We may infringe, misappropriate, or otherwise violate the intellectual property rights of others, and be subject to legal proceedings alleging the same, which may prevent or delay our drug development efforts and prevent us from commercializing, or increase the costs of commercializing, our products.
  • We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful.
  • We may become subject to claims challenging the inventorship or ownership of our owned or licensed patent rights and other intellectual property, or claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. If we do not obtain patent term extension, or the foreign equivalent, for our product candidates, our business may be materially harmed.
  • Obtaining and maintaining our patent protection is dependent on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build brand and name recognition in our markets of interest and our business may be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats to our business.
  • We may not be able to obtain, maintain and protect our intellectual property rights throughout the world.
  • Risks Related to Government Regulation
  • Even if we commercialize any product candidates, such product may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which could harm our business.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.
  • Our current and future relationships with healthcare providers and physicians and third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
  • We may seek a Breakthrough Therapy or Fast Track designation or priority review voucher for current or future product candidates, but we might not receive such designation, and even if we do, we may not maintain such designation. Such designation may not lead to faster development, regulatory review, or approval, and will not increase the likelihood that the product candidate will receive marketing approval.
  • Recently enacted legislation, future legislation, and other healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.
  • Even if we receive marketing approval for our current or future product candidates in the United States, we may never receive regulatory approval to market outside of the United States.
  • We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.
  • Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing, and selling certain product candidates we may identify outside of the United States, and require us to develop and implement costly compliance programs.
  • If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could adversely affect our business, financial condition, and results of operations.
  • Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could adversely affect our business.
  • The increasing use of social media platforms presents new risks and challenges.
  • Risks Related to Data Privacy, Information Technology, and Cybersecurity
  • If our information technology systems, or those used by our CROs, CMOs, clinical sites, or other contractors, consultants, or third parties with whom we work, or our data are or were compromised, including by system failures, security incidents, or loss or leakage of data, or otherwise disrupted, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or action, litigation, fines and penalties, disruptions of our business operations, reputational harm, and other adverse consequences.
  • Risks Related to Our Reliance on Third Parties
  • We have relied and expect to continue to rely on third parties to assist us as we conduct aspects of our preclinical studies and clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines, or terminate their relationship with us, our development programs could be delayed, made more costly, or fail to yield interpretable results, and we may never be able to seek or obtain regulatory approval for, or commercialize our product candidates.
  • We rely on third-party manufacturers and suppliers to supply our product candidates. The loss of our third-party manufacturers or suppliers, or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, within acceptable timeframes, or at all, would materially and adversely affect our business, financial condition, results of operations, and prospects.
  • Some of our suppliers are located outside of the United States, which subjects us to additional risks that are beyond our control and that could harm our business, financial condition, results of operations, and prospects.
  • General Risk Factors
  • Our stock price may be volatile, and investors in our common stock could incur substantial losses.
  • We or our directors or officers may be subject to securities litigation, which is expensive and could divert management attention.
  • Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance we may publicly provide, which may cause our stock price to fluctuate or decline.
  • Because we do not anticipate paying any dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
  • Our board of directors is authorized to issue and designate shares of our preferred stock without stockholder approval.
  • We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
  • We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders.

Legal proceedings

From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35